Evofem Biosciences, Inc. (EVFM)

Evofem Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	16.01	18.22	16.84	8.24	0.45	0
Revenue Growth (YoY)	-12.95%	8.20%	104.23%	1748.43%	-	-
Cost of Revenue	5.95	8.29	4.42	4.06	0.47	0.91
Gross Profit	10.07	9.93	12.42	4.19	-0.02	-0.91
Selling, General & Admin	24.22	25.31	71.51	137.86	86.55	30.51
Research & Development	2.96	2.46	25.03	33.13	17.05	22.23
Other Operating Expenses	-6.2	-2.63	-2.09	-4.73	-2.08	-19.99
Operating Expenses	27.18	27.77	96.55	170.99	103.6	52.74
Operating Income	-17.11	-17.85	-84.12	-166.8	-103.62	-52.74
Interest Income	0.02	0.03	0.09	0.02	0.17	0.46
Interest Expense	0	0	-17.96	0	0	0
Other Expense / Income	-67.63	-70.81	10.57	38.39	38.85	27.75
Pretax Income	50.54	53	-76.65	-205.18	-142.31	-80.03
Income Tax	0.01	0.02	0.04	0.02	0	0
Net Income	50.52	52.98	-76.7	-205.19	-142.31	-80.03
Shares Outstanding (Basic)	31	5	0	0	0	0
Shares Outstanding (Diluted)	31	984	0	0	0	0
Shares Change	2355.91%	209270.21%	571.43%	75.00%	100.00%	71.23%
EPS (Basic)	9.66	10.36	-163.19	-2931.31	-3557.72	-4001.65
EPS (Diluted)	-5.58	0.05	-163.19	-2931.31	-3557.72	-4001.65
Free Cash Flow	-3.92	-8.97	-70.75	-149.61	-107.08	-55.26
Free Cash Flow Per Share	-0.13	-0.01	-150.53	-2137.23	-2677.07	-2763.05
Gross Margin	62.87%	54.48%	73.78%	50.81%	-4.93%	-
Operating Margin	-106.87%	-97.96%	-499.64%	-2023.30%	-23234.08%	-
Profit Margin	315.54%	290.81%	-455.53%	-2488.99%	-31907.85%	-
Free Cash Flow Margin	-24.48%	-49.25%	-420.21%	-1814.73%	-24009.64%	-
Effective Tax Rate	0.03%	0.03%	-	-	-	-
EBITDA	-86.84	-16.07	-93.6	-133.14	-66.86	-44.99
EBITDA Margin	-542.33%	-88.19%	-555.89%	-1615.04%	-14990.13%	-
Depreciation & Amortization	0.34	1.78	1.02	1.02	0.3	0.26
EBIT	-87.17	-17.85	-94.61	-134.17	-67.16	-45.25
EBIT Margin	-544.43%	-97.96%	-561.92%	-1627.45%	-15057.85%	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.